OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Adige on the Importance of Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses the importance of recognizing Breast Cancer Awareness Month and highlights key insights into understanding the disease.

Dr Jain on Treatment Considerations in the Frontline Management of CLL

October 9th 2024

Nitin Jain, MD, discusses current treatment options and considerations for the frontline management of CLL.

Dr Ng on Treatment Considerations for Younger Patients With CRC

October 9th 2024

Kimmie Ng, MD, MPH, discusses treatment considerations for younger patients with colorectal cancer.

Dr Garassino on the Potential Use of a TROP2 Biomarker to Predict Outcomes With Dato-DXd in NSCLC

October 8th 2024

Marina Chiara Garassino, MD, discusses the predictive utility of a TROP2 computational pathway biomarker for outcomes with Dato-DXd in pretreated NSCLC.

Dr Jabbour on the Role of Bosutinib as a Therapeutic Option for TKI-Pretreated CML

October 8th 2024

Elias Jabbour, MD, discusses the role of bosutinib as a standard treatment for patients with CML that is resistant or intolerant to prior TKI therapy.

Dr Banerjee on Future Hopes For Bispecific Antibody Therapy in Myeloma

October 8th 2024

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

Dr Wander on Managing HR+ Advanced Breast Cancer in the Clinic

October 8th 2024

Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.

Dr Rutkowski on Avelumab Plus Axitinib in Unresectable/Metastatic GIST

October 8th 2024

Piotr Rutkowski, MD, discusses an investigation of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression.

Dr Martín-Broto on the Efficacy of Sunitinib Plus Nivolumab in Clear Cell Sarcoma

October 8th 2024

Javier Martín Broto MD, PhD, discusses the efficacy of treatment with sunitinib plus nivolumab in clear cell sarcoma, according to the IMMUNOSARC II trial.

Dr Girard on the Safety of Nivolumab/Relatlimab/Chemotherapy in Untreated NSCLC

October 8th 2024

Nicolas Girard, MD, discusses the safety of nivolumab plus relatlimab and chemotherapy for untreated stage IV or recurrent non–small cell lung cancer.

Dr Truong on Targeted Therapy vs Immunotherapy in BRAF V600–Positive Melanoma

October 7th 2024

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.

Dr Sonpavde on Early Data With Sacituzumab Govitecan Plus Ipilimumab/Nivolumab in Urothelial Cancer

October 7th 2024

Guru P. Sonpavde, MD, discusses initial data from a phase 1/2 trial of sacituzumab govitecan plus ipilimumab and nivolumab in metastatic urothelial cancer.

Dr Janjigian on Final OS Results With Pembrolizumab Plus Trastuzumab and Chemo in HER2+ Gastric/GEJ Cancer

October 7th 2024

Yelena Y. Janjigian, MD, discusses final overall survival data from the phase 3 KEYNOTE-811 trial in HER2-positive metastatic gastric or GEJ adenocarcinoma.

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

October 7th 2024

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Dr Peng on the Efficacy of SHR-1701 Plus Chemotherapy in HER2– Gastric/GEJ Cancer

October 7th 2024

Zhi Peng, MD, discusses a study of SHR-1701 vs placebo in combination with chemotherapy in the first-line management of HER2– gastric/GEJ adenocarcinoma.

Dr Llovet on the Efficacy of TACE With or Without Lenvatinib Plus Pembrolizumab in HCC

October 7th 2024

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC

October 4th 2024

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC

October 4th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses next steps for the investigation of darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer

October 4th 2024

Eric Kumar Singhi, MD, discusses the identification of current care gaps and unmet needs in small cell lung cancer.

Dr Wander on Limitations of First- and Later-Line Therapies in HR+ Breast Cancer

October 4th 2024

Seth Wander, MD, PhD, discusses the present limitations of first- and later-line therapy for HR+ metastatic breast cancer.